US Markets

Japan's Fujifilm gets $265 mln U.S. contract to boost output of potential virus vaccine

The United States has awarded a $265 million contract to a Texas facility of Japan's Fujifilm Holdings Corp to step up production of a coronavirus vaccine candidate, President Donald Trump said.

TOKYO, July 28 (Reuters) - The United States has awarded a $265 million contract to a Texas facility of Japan's Fujifilm Holdings Corp 4901.T to step up production of a coronavirus vaccine candidate, President Donald Trump said.

Trump made the announcement on Monday, as he toured another Fujifilm facility in North Carolina. The order widens a pact between the Department of Health and Human Services, the Texas A&M university system and Fujifilm Diosynth Biotechnologies.

The funds will speed by several months an expansion planned at the Texas facility in College Station, with completion now expected this fall, Fujifilm said in a news release.

Last week, Fujifilm Diosynth, a drug ingredient subsidiary of the Japanese firm, said it would make bulk drug substances for Novavax Inc.'s NVAX.O virus vaccine candidate, NVX-CoV2373.

It added that it would spend $928 million to double capacity at a Denmark facility that is also involved in making virus treatments.

The company's shares climbed 3.2% in Tokyo in a flat overall market.

(Reporting by Rocky Swift; Editing by Clarence Fernandez)

((rocky.swift@thomsonreuters.com;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

NVAX

Latest Markets Videos

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More